目次

Table of Content

1. Introduction To CD40 Targeted Therapies
1.1 Overview
1.2 Considering CD40 As Drug Target Over Other CD Markers
1.3 History and Evolution Of CD40 Targeting Therapies

2. CD40 Targeted Therapies - Mechanism Of Action
2.1 Agonist Mediated Activation Of CD40 Signaling
2.2 Antagonist Mediated Inhibition Of CD40 Signaling

3. CD40 Targeted Therapeutic Approaches
3.1 Antibody Formats
3.2 Fusion Proteins
3.3 Peptides
3.4 Nucleic Acids

4. CD40 Targeted Therapy Research and Development Trends By Indication
4.1 Cancer
4.2 Neurological Diseases
4.3 Autoimmune and Inflammatory Disorders
4.4 Transplant Rejection
4.5 Microbial Infections

5. CD40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase
5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase I/II
5.5 Phase II
5.6 Phase III

6. Global CD40 Targeted Therapy Market Outlook
6.1 Current Market Trends and Developments
6.2 Future Market Opportunities

7. CD40 Targeted Therapy Market Trend Analysis By Region
7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 Australia

8. CD40 Targeted Therapies - Proprietary Technologies By Company

9. Global CD40 Targeted Therapy Market Dynamics
9.1 Drivers and Opportunities
9.2 Challenges and Restraints

10. Competitive Landscape
10.1 Alligator Bioscience
10.2 Amgen
10.3 Biogen
10.4 BioNTech
10.5 Eledon Pharmaceuticals
10.6 EnnoDC
10.7 Genmab
10.8 Innovent Bio
10.9 Novartis
10.10 Sanofi
10.11 Tonix Pharmaceuticals
10.12 UCB

List of Figures
Figure 1-1: CD40 - Salient Features
Figure 1-2: CD40 Targeted Therapy Landscape - Major Milestones
Figure 2-1: CD40 Agonists - Mechanism Of Action
Figure 2-2: CD40 Antagonists - Mechanism Of Action
Figure 3-1: Prominent Antibody Formats For Targeting CD40
Figure 3-2: CD40 Fusion Protein Types and Properties
Figure 3-3: CD40 Fusion Proteins - Advantages and Challenges
Figure 3-4: Advantages vs. Challenges Of Peptides For CD40 Targeting
Figure 3-5: siRNA Delivery Mechanism and Effect On Immune Cells
Figure 4-1: OPTIMIZE-1 Phase 1b/2 (NCT04888312) Study - Initiation and Completion Year
Figure 4-2: Mitazalimab Phase 1 (NCT06205849) Study - Initiation and Completion Year
Figure 4-3: 2141-V11 Phase 1 (NCT06455605) Study - Initiation and Completion Year
Figure 4-4: 2141-V11 Phase 1/2 (NCT05734560) Study - Initiation and Completion Year
Figure 4-5: 2141-V11 Phase 1/2 (NCT05126472) Study - Initiation and Completion Year
Figure 4-6: ACT16877 Phase 2 (NCT04879628) Study - Initiation and Completion Year
Figure 4-7: FREVIVA Phase 3 (NCT06141486) Study - Initiation and Completion Year
Figure 4-8: FREXALT 3 (NCT06141473) Study - Initiation and Completion Year
Figure 4-9: PHOENYCS FLY Phase 3 (NCT06617325) Study - Initiation and Completion Year
Figure 4-10: SL0046 Phase 3 (NCT04976322) Study - Initiation and Completion Year
Figure 4-11: HZNP-DAZ-301 Phase 3 (NCT06104124) Study - Initiation and Completion Year
Figure 4-12: HZNP-DAZ-303 Phase 3 (NCT06245408) Study - Initiation and Completion Year
Figure 4-13: VIBRANT Phase 2 (NCT05201469) Study - Initiation and Completion Year
Figure 4-14: FABULINUS Phase 2 (NCT06111586) Study - Initiation and Completion Year
Figure 4-15: APB-A1 Phase 1b (NCT06557850) Study - Initiation and Completion Year
Figure 4-16: IRB23-1367 Phase 1/2 (NCT06111586) Study - Initiation and Completion Year
Figure 4-17: AT-1501-K102 Phase 1 (NCT05027906) Study - Initiation and Completion Year
Figure 4-18: BESTOW/AT-1501-K207 Phase 2 (NCT05983770) Study - Initiation and Completion Year
Figure 4-19: BESTOW-EXTENSION/AT-1501-K209 Phase 2 (NCT06126380) Study - Initiation and Completion Year
Figure 4-20: ANRS VRI06 Phase 1 (NCT04842682) Study - Initiation and Completion Year
Figure 4-21: HVTN 318 Phase 1 (NCT06665646) Study - Initiation and Completion Year
Figure 4-22: ANRS0407s - LKV.Cov40 Phase 1/2 (NCT06255626) Study - Initiation and Completion Year
Figure 4-23: HPVDCVax Phase 1/2 (NCT06007092) Study - Initiation and Completion Year
Figure 5-1: Global - CD40 Targeted Therapies In Clinical Trials, 2025 -2026
Figure 6-1: CD40 Targeted Therapy - Future Opportunities
Figure 8-1: Alligator Bioscience - FIND technology
Figure 8-2: Alligator Bioscience - Neo-X-Prime
Figure 8-3: Aprilbio - SAFA Antibody APB-A1
Figure 8-4: Genmab - DuoBody
Figure 8-5: Harbour BioMed - Harbour Mice
Figure 8-6: Harbour BioMed - HCAb
Figure 8-7: H2L2 and HCAb Platforms - Features
Figure 8-8: Harbour BioMed - HBICE
Figure 8-9: Kyowa Kirin - REGULGENT
Figure 8-10: ADAC Technology Platform - Features
Figure 8-11 Strike Pharma - ADAC Technology Platform
Figure 8-12: Strike Pharma - ADAC Molecule
Figure 9-1: CD40 Targeted Therapy Market - Drivers and Opportunities
Figure 9-2: CD40 Targeted Therapy Market - Challenges and Restraints

List Of Tables
Table 3-1: Comparison Of siRNA vs. Anti-CD40 Antibody Therapy
Table 5-1: CD40 Targeted Therapies In Research Stage, 2025 - 2026
Table 5-2: CD40 Targeted Therapies In Preclinical Stage, 2025 - 2026
Table 5-3: CD40 Targeted Therapies In Phase I, 2025 - 2026
Table 5-4: CD40 Targeted Therapies In Phase I/II, 2025 - 2026
Table 5-5: CD40 Targeted Therapies In Phase II, 2025 - 2026
Table 5-6: CD40 Targeted Therapies In Phase III, 2025 - 2026
Table 6-1: CD40 Targeted Therapies In Phase III Clinical Trials